Page 1 | Search Results | Blood | American Society of Hematology

1-14 of 14

Sort by

Sort Order Select

Journal Articles

Fatigue, Quality of Life, and Physical Fitness Following an Exercise Intervention in Survivors of Multiple Myeloma: A Randomised Controlled Trial Using a Zelen Design

Joanne Sowter, MSc, Dimitrios A Koutoukidis, PhD, Maggie Heinrich, PhD, Orla McCourt, MSc, Allan Hackshaw, Rebecca Beeken, PhD, Dunnya De-Silva, Stephanie Philpott, MSc, Ali Rismani, MBBS, Neil K Rabin, MD, Rakesh Popat, MBBS, BSc, MRCP, FRCPath, PhD, Charalampia Kyriakou, MD PhD, Atul Mehta, FRCP, Bruce Paton, PhD, Abigail Fisher, PhD, Kwee Yong, PhD

Blood (2018) 132 (Supplement 1): 974.

https://doi.org/10.1182/blood-2018-99-111403

Published: 2018

Journal Articles

A Global Delphi Consensus Initiative for Early Diagnosis of Gaucher Disease: Barriers, Their Resolution and the Impact on Patients

David J Kuter, MD DPhil, Sam Salek, PhD, Atul Mehta, MD

Blood (2016) 128 (22): 4885.

https://doi.org/10.1182/blood.V128.22.4885.4885

Published: 2016

Journal Articles

Key Presenting Signs and Patient Co-Variables in Early Diagnosis of Type 3 Gaucher Disease: A Global Delphi Consensus Initiative

David J Kuter, MD DPhil, Sam Salek, PhD, Atul Mehta, MD

Blood (2016) 128 (22): 4886.

https://doi.org/10.1182/blood.V128.22.4886.4886

Published: 2016

Journal Articles

A Global Delphi Consensus Initiative for Early Diagnosis of Gaucher Disease: Key Presenting Signs and Patient Co-Variables in Type 1 Disease

David J Kuter, MD DPhil, Sam Salek, PhD, Atul Mehta, MD

Blood (2016) 128 (22): 3676.

https://doi.org/10.1182/blood.V128.22.3676.3676

Published: 2016

Journal Articles

Vial Sharing of Bortezomib Is Logistically Feasible and Significantly Reduces Drug Wastage and the Cost of Myeloma Treatment

Simon Cheesman, Aoife Shields, Raakhee Shah, Nisha Thakrar, Jeff Bradley, Tom Marler-Hausen, Shirley D'Sa, Charalampia Kyriakou, Atul Mehta, MD, Rakesh Popat, Neil Rabin, Ali Rismani, MBBS, Kwee L Yong, Ashu Wechalakar

Blood (2016) 128 (22): 5956.

https://doi.org/10.1182/blood.V128.22.5956.5956

Published: 2016

Journal Articles

Physical and Psychological Factors Influencing Fatigue and Quality of Life in Multiple Myeloma Survivors: Preliminary Results from the Mascot Lifestyle Study

Malgorzata Heinrich, PhD, Joanne Land, BSc, Orla McCourt, MSc, Stephanie Philpott, MSc, Bruce Paton, PhD, Rebecca J Beeken, PhD, Lee Smith, PhD, Dunnya De-Silva, MBBS, Ali Rismani, MBBS, Shirley D'Sa, Anastasia Chew, MBBS, MRCP, FRCPATH, Atul Mehta, MD, Abigail Fisher, PhD, Allan Hackshaw, PhD, Kwee L Yong

Blood (2016) 128 (22): 4776.

https://doi.org/10.1182/blood.V128.22.4776.4776

Published: 2016

Journal Articles

Duration of Therapy Is Independently Associated with Improved Progression Free and Overall Survival Following First Line Therapy for Non-Transplant Eligible Patients with Multiple Myeloma: Retrospective Analysis from a Single Centre

Dunnya De-Silva, MBBS, Adam Bloomfield, Nicholas Counsell, Simon Cheesman, BPharm, Ali Rismani, MBBS, Neil Rabin, Shirley D'Sa, Charalampia Kyriakou, Jayne Galinsky, Sarah Richard, Rakesh Popat, Atul Mehta, MD, Kwee L Yong

Blood (2016) 128 (22): 5684.

https://doi.org/10.1182/blood.V128.22.5684.5684

Published: 2016

Journal Articles

Cancer-Selective Targeting of the NF-κB Survival Pathway in Multiple Myeloma with the GADD45β/MKK7 Inhibitor, DTP3

Blood (2015) 126 (23): 868.

https://doi.org/10.1182/blood.V126.23.868.868

Published: 2015

Journal Articles

Zimran A, Brill-Almon E, Chertkoff R, et al. Pivotal trial with plant cell–expressed recombinant glucocerebrosidase, taliglucerase alfa, a novel enzyme replacement therapy for Gaucher disease. Blood . 2011;118(22): 5767–5773 .

Blood (2012) 119 (19): 4577.

https://doi.org/10.1182/blood-2012-01-408054

Published: 2012

Journal Articles

Pivotal trial with plant cell–expressed recombinant glucocerebrosidase, taliglucerase alfa, a novel enzyme replacement therapy for Gaucher disease

Blood (2011) 118 (22): 5767–5773.

https://doi.org/10.1182/blood-2011-07-366955

Published: 2011

Journal Articles

Miglustat Therapy in Type 1 Gaucher Disease: Long-Term Treatment Experience From a Multicenter, Retrospective Cohort Study,

David J. Kuter, MD, DPhil, Atul Mehta, MD, Carla Hollak, MD, PhD, Pilar Giraldo, MD, PhD, Derralynn Hughes, MRCP, MRCPath, DPhil, MA, Nadia Belmatoug, MD, Monika Brand, Audrey Muller, Berthold Schaaf, Ruben Giorgino, Ari Zimran, MD

Blood (2011) 118 (21): 3207.

https://doi.org/10.1182/blood.V118.21.3207.3207

Published: 2011

Journal Articles

Variation of Serum Lipid Profile during Enzyme Replacement Therapy, in Patients with Type 1 Gauchers Disease.

Argiris Symeonidis, Derralynn Hughes, Linda Richfield, Atul Mehta

Blood (2006) 108 (11): 3849.

https://doi.org/10.1182/blood.V108.11.3849.3849

Published: 2006

Journal Articles

Conserved Amino Acid Sequences Occur in a Limited Group of CLL Patients with Predominantly Mutated IGH Rearrangements.

Veronique M. Duke, BSc PhD, Birithini Yogashangari, BSc, Domenica Gandini, MD PhD, Paul D. Sherrington, MD PhD, Atul Mehta, MD, A. Victor Hoffbrand, Letizia Foroni, MD PhD

Blood (2004) 104 (11): 2000.

https://doi.org/10.1182/blood.V104.11.2000.2000

Published: 2004

Journal Articles

Hepcidin Dysregulation in Patients with Type 1 Gaucher’s Disease.

Derralynn A. Hughes, MA DPhil MRCP, Anna Li, BSc, Satish Keshav, DPhil FRCP, Atul Mehta, MD FRCP FRCPath

Blood (2004) 104 (11): 3824.

https://doi.org/10.1182/blood.V104.11.3824.3824

Published: 2004

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

Fatigue, Quality of Life, and Physical Fitness Following an Exercise Intervention in Survivors of Multiple Myeloma: A Randomised Controlled Trial Using a Zelen Design

A Global Delphi Consensus Initiative for Early Diagnosis of Gaucher Disease: Barriers, Their Resolution and the Impact on Patients

Key Presenting Signs and Patient Co-Variables in Early Diagnosis of Type 3 Gaucher Disease: A Global Delphi Consensus Initiative

A Global Delphi Consensus Initiative for Early Diagnosis of Gaucher Disease: Key Presenting Signs and Patient Co-Variables in Type 1 Disease

Vial Sharing of Bortezomib Is Logistically Feasible and Significantly Reduces Drug Wastage and the Cost of Myeloma Treatment

Physical and Psychological Factors Influencing Fatigue and Quality of Life in Multiple Myeloma Survivors: Preliminary Results from the Mascot Lifestyle Study

Duration of Therapy Is Independently Associated with Improved Progression Free and Overall Survival Following First Line Therapy for Non-Transplant Eligible Patients with Multiple Myeloma: Retrospective Analysis from a Single Centre

Cancer-Selective Targeting of the NF-κB Survival Pathway in Multiple Myeloma with the GADD45β/MKK7 Inhibitor, DTP3

Zimran A, Brill-Almon E, Chertkoff R, et al. Pivotal trial with plant cell–expressed recombinant glucocerebrosidase, taliglucerase alfa, a novel enzyme replacement therapy for Gaucher disease. Blood . 2011;118(22): 5767–5773 .

Pivotal trial with plant cell–expressed recombinant glucocerebrosidase, taliglucerase alfa, a novel enzyme replacement therapy for Gaucher disease

Miglustat Therapy in Type 1 Gaucher Disease: Long-Term Treatment Experience From a Multicenter, Retrospective Cohort Study,

Variation of Serum Lipid Profile during Enzyme Replacement Therapy, in Patients with Type 1 Gauchers Disease.

Conserved Amino Acid Sequences Occur in a Limited Group of CLL Patients with Predominantly Mutated IGH Rearrangements.

Hepcidin Dysregulation in Patients with Type 1 Gaucher’s Disease.

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only